En Es
Categories

Industry News


Seegene Unveils Combination Test at ECCMID 2018

By Labmedica International staff writers
19 Apr 2018

Image: At ECCMID 2018, Seegene showcased its molecular diagnostic system SGSTAR, which allows order-to-report on the same day and enables the running of the combination test (Photo courtesy of Seegene).Seegene Inc. (Seoul, South Korea), a developer of multiplex PCR technologies, introduced a combination test at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) held in Madrid, Spain, from April 21 to 24, 2018. The combination test is a high-efficiency solution that diagnoses various causes of diseases with multiplex molecular diagnosis assays. Seegene also showcased its molecular diagnostic system SGSTAR (Seegene Sameday Test and Report), which allows order-to-report on the same day and enables the running of the combination test.

Seegene develops multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Its core enabling technologies are the foundation for M-MoDx tests which can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. The combination test introduced by Seegene at the ECCMID 2018 can detect pathogens for syndromic infectious diseases by simultaneously performing all possible tests for pathogens sharing similar symptoms from the same type of specimen. For instance, in a patient with respiratory symptoms, the combination test can reveal the cause of the disease by simultaneously diagnosing whether the relevant symptoms are caused by tubercule bacillus or pneumococcus. The combination test is available for tuberculosis and pneumonia, as well as for HPV and sexually transmitted infections and full panel tests for gastrointestinal infections.

The company’s molecular diagnostic system SGSTAR, which was also showcased at the ECCMID 2018, is an innovative MDx solution that provides order-to-report on the same day by simultaneously performing high multiplex real-time PCR testing on a single platform, irrespective of the specimen and assay type. With this system solution, the combination test can be concurrently implemented, and the test results can be provided on the very day of the patient's visit to the hospital.

"In order to achieve on-time customized patient care and to foster a comprehensive delivery medical care to patients, a more objective and accurate testing method based on symptoms and samples is necessary. We believe that Seegene's combination test will be a breakthrough in achieving this," said Dr. Jong-Yoon Chun, founder and CEO of Seegene. "If the combination test is broadly applied, the exact cause of infectious diseases can be identified and treated. This not only contributes to the improvement in patient care, but also medical institutions and reimbursement system can save time and costs, which could create new value-added to the molecular diagnostic industry."



E-mail Print
FaceBook Twitter Google+ Linked in

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology. The company’s products detect multi-pathogens with high sensitivity, specificity and reproducibility, resulting in saving of time, labor and cost.
Gold member
More info

More articles about Seegene

09 Jan 2018
Seegene Develops World’s First Multiplex MDx Assays with AI System
Seegene Inc., a developer of multiplex PCR technologies, successfully developed molecular diagnostics (MDx) assays in just four days using an artificial intelligence- (AI) based automated assay development system. These assays are high multiplex real-time PCR reagents developed completely by AI and are meant for the simultaneous detection of eight different DNA targets for each of meningitis and sexually transmitted infections.
Read More
28 Sep 2017
Seegene Partners with Hamilton to Develop Random Access System
Seegene, a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx), has signed a Memorandum of Understanding (MoU) with Hamilton Company, which designs and manufactures precision measurement devices, automated liquid handling workstations, and sample management systems, to develop the Seegene Random Access System.
Read More
29 May 2017
Seegene Collaborates with Thermo to Enter US Market
Seegene Inc., a developer of multiplex molecular diagnostics technologies and assays, has entered into a collaboration with Thermo Fisher Scientific, in which Seegene will file for U.S. Food and Drug Administration (FDA) clearance of its Allplex diagnostic assay portfolio at the same time that Thermo Fisher files for FDA clearance to run Seegene's assays on Thermo Fisher's QuantStudio 5 Real-Time PCR System (PCR System).
Read More

Additional news

26 Jul 2021
GE Healthcare Backs Development of Innovative Total-Body PET/CT Scanner for Simultaneous Whole-Body Imaging
GE Healthcare (Chicago, IL, USA) is backing a collaboration among Quibim (Valenciana, Spain), Full Body Insight, and Oncovision (Valenciana, Spain) to build an innovative total-body PET/CT scanner for simultaneous whole-body imaging.
Read More
23 Jul 2021
RSNA 2021 to Be In-Person Event with Demonstrations of Latest Medical Imaging Technologies in CT, MRI and AI
The world's largest radiology forum is all set to offer robust in-person scientific assembly and technical exhibition with demonstrations of the latest medical imaging technologies in CT, MRI, artificial intelligence (AI), 3D printing and more.
Read More
21 Jul 2021
BD Seeks to Transform Patient Experience Through Vision of 'One-Stick Hospital Stay'
Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA) has taken a large step forward in transforming the patient experience through a vision of a "One-Stick Hospital Stay," building on its history of innovation and leadership in blood collection and vascular access solutions.
Read More
19 Jul 2021
ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC
ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders.
Read More
16 Jul 2021
DiaSorin Completes Acquisition of Luminex to Become a Full-Fledged Diagnostic and Life Science Player
DiaSorin S.p.A. (?Saluggia?, Italy) has completed the acquisition of Luminex Corporation (Austin, TX, USA), allowing it to gain access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the US.
Read More
14 Jul 2021
Global Smart Hospitals Market to Reach USD 221.3 Billion by 2030 Due to Proliferation of ML, AI and IoT
The global smart hospitals market is expected to reach USD 221.3 billion by the end of 2030 due to health professionals increasing their usage of electronic health records and connected medical assistance.
Read More
13 Jul 2021
AI Diagnostic Tool Analyzes CT Scans to Spot Prostate Cancer Before Patients Have Symptoms
Researchers have developed a diagnostic tool that can spot prostate cancer before patients have any symptoms, using artificial intelligence to analyze Computed Tomography (CT) scans in just seconds.
Read More
13 Jul 2021
Instrumentation Laboratory, Inova Diagnostics and Biokit Organizationally Transform and Now Share Werfen Name
Werfen (Barcelona, Spain) companies, including Instrumentation Laboratory (IL), Inova Diagnostics (Inova), and Biokit, are uniting under one name and one brand - Werfen. As part of this effort, the company has completed organizational transitions and adopted a new global brand identity, including a new corporate logo.
Read More
08 Jul 2021
Global AI-Based Surgical Robots Market to Reach USD 17.2 Billion by 2028
The global AI-based surgical robots market size is expected to expand at a CAGR of 17.2% from 2021 to 2028 to reach USD 17.2 billion by 2028, driven by increased efficiency and success rate offered by robotic surgeries, along with a shift in the preference for minimally invasive surgeries by patients over traditional methods.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions